BioPoly

Approved

Fort Wayne, United StatesFounded 2004biopolyortho.com

BioPoly, a spin-off from Schwartz Biomedical, is pioneering a novel class of orthopedic implants with its patented BioPoly material, which mimics natural cartilage function. The company has commercial products for the toe and radial head, an FDA-approved knee implant in clinical study, and is focused on expanding its pipeline for joint preservation. Founded and led by a team of seasoned experts in Fort Wayne, Indiana, BioPoly aims to bridge the gap between biological treatments and total joint arthroplasty.

Founded

2004

AI Company Overview

Technology Platform

Proprietary composite biomaterial combining hyaluronic acid for lubrication and ultra-high molecular weight polyethylene for strength, creating a self-lubricating, durable synthetic cartilage designed for partial joint resurfacing.

Funding History

Total raised: $19.0M

Series A$15MUndisclosedAug 15, 2021

Seed$2.5MUndisclosedNov 15, 2019

Grant$121KNEIAug 31, 2006

Grant$400KNHLBIJul 15, 2003

Opportunities

The primary growth opportunity is U.S.

market entry for the knee implant, targeting the large population with focal cartilage defects.

Further pipeline expansion into other joints (shoulder, hip, ankle) and geographic expansion outside the U.S.

represent significant long-term growth avenues.

Risk Factors

Key risks include the clinical and regulatory failure of the pivotal knee implant study, challenges in achieving surgeon adoption for a new material/technique, and competition from large orthopedic incumbents with greater resources.

Competitive Landscape

Competes with other synthetic cartilage/partial resurfacing companies (e.g., Cartiva, Moximed) and biological repair firms. Differentiation lies in its proprietary self-lubricating BioPoly material, which is designed to be durable and articulate safely against natural cartilage.